Shif Jennifer, Tasissa Hawi, MacDougall Conan, Heil Emily L, Gallagher Jason C
School of Pharmacy, Temple University, Philadelphia, Pennsylvania, USA.
University of California San Francisco Medical Center, San Francisco, California, USA.
Open Forum Infect Dis. 2025 Sep 3;12(9):ofaf435. doi: 10.1093/ofid/ofaf435. eCollection 2025 Sep.
Oral β-lactams are frequently referred to as low bioavailability agents that are inferior in the treatment of systemic gram-negative infections. This notion limits their utility beyond their use. The pharmacokinetic/pharmacodynamic profiles of oral β-lactams differ among agents, and each agent must be considered individually in the context of the patient. In this review, we describe 3 scenarios where oral β-lactams may play a role in the treatment of systemic gram-negative infections and the decision process to select or avoid these agents. Each case represents a risk-vs-benefit scenario in which the degree of confidence in using an oral β-lactam varies.
口服β-内酰胺类药物常被视为生物利用度低的药物，在治疗全身性革兰氏阴性菌感染方面效果较差。这种观念限制了它们除现有用途之外的效用。不同的口服β-内酰胺类药物的药代动力学/药效学特征有所不同，必须根据患者的具体情况对每种药物进行单独考虑。在本综述中，我们描述了口服β-内酰胺类药物可能在全身性革兰氏阴性菌感染治疗中发挥作用的3种情况以及选择或避免使用这些药物的决策过程。每个案例都代表了一个风险与收益的情景，在这些情景中，使用口服β-内酰胺类药物的信心程度各不相同。
